The reputation of the pharmaceutical industry among patients in the US has fallen to a minimum in recent years. Some experts note that the policy of current president could have caused such reaction.
Only 29% of the recently interviewed respondents by the research firm PatientView believe that representatives of the pharmaceutical industry have “excellent” or “good” corporate reputation. This is the most negative rating in the US since 2013. In the global community, 38% of patients positively assess the reputation of pharmaceuticals, reports PatientView.
PatientView founder and CEO Alex Wyke said in an interview that U.S. President Donald Trump may have something to do with the stat.
“Trump has changed the whole dynamics in the way pharma companies are viewed, not just in the USA but worldwide. 2016 was notable in that patient groups marked the industry down for many of their activities, but most notable was the ability of companies to adopt fair pricing policies—from the perspective of patient groups,” he said via email.
However, there were some positive assessments. Patients noted positive changes in pharmaceutical companies in the field of innovation, providing high-quality information, access to clinical trials, working with patients, and, in their view, companies operating in the US are becoming more philanthropic. Estimates for these parameters were higher in comparison with the worldwide trend in the polls of patients from 19 other countries.
PatientView’s survey also ranks individual pharma companies by their reputations among U.S. groups and found that Roche, Shire, Amgen, Allergan, Novo Nordisk and Novartis notched the most significant gains with patient groups year over year.